These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 19357513

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
    Kawamura K, Suzuki H, Kamiya N, Imamoto T, Yano M, Miura J, Shimbo M, Suzuki N, Nakatsu H, Ichikawa T.
    Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK, Prostate, Lung, Colorectal and Ovarian Project Team.
    J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
    [Abstract] [Full Text] [Related]

  • 10. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
    Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR.
    Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
    [Abstract] [Full Text] [Related]

  • 11. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
    Eggener SE, Roehl KA, Catalona WJ.
    J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
    [Abstract] [Full Text] [Related]

  • 12. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI.
    Cancer; 2008 Nov 15; 113(10):2695-703. PubMed ID: 18853417
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
    Kawakami S, Koga F, Fujii Y, Saito K, Yamamoto S, Tatokoro M, Yonese J, Kageyama Y, Fukui I, Kihara K.
    Int J Urol; 2008 Dec 15; 15(12):1055-60. PubMed ID: 19054174
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH.
    Eur Urol; 2007 Nov 15; 52(5):1358-64. PubMed ID: 17499425
    [Abstract] [Full Text] [Related]

  • 17. Prostate cancer risk assessment program: a 10-year update of cancer detection.
    Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, Hanks G, Godwin AK, Chen DY, Gordon R, Cescon T, Raysor S, Watkins-Bruner D.
    J Urol; 2007 Nov 15; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.